Your browser doesn't support javascript.
loading
EGPA: Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) as a special presentation of chronic rhinosinusitis with nasal polyps (CRSwNP).
Hagemann, Jan; Laudien, Martin; Becker, Sven; Cuevas, Mandy; Klimek, Felix; Kianfar, Roya; Casper, Ingrid; Klimek, Ludger.
Afiliación
  • Hagemann J; Clinic for Ear, Nose and Throat Medicine, Mainz University Medical Center, Mainz.
  • Laudien M; Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Becker S; Clinic for Ear, Nose and Throat Medicine, University Medicine Kiel, Kiel.
  • Cuevas M; Clinic and Polyclinic for ENT Medicine, University Hospital Tübingen, Tübingen.
  • Klimek F; Clinic and Polyclinic for ENT Medicine, Carl Gustav Carus University Hospital, TU Dresden, Dresden, and.
  • Kianfar R; Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Casper I; Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Klimek L; Center for Rhinology and Allergology, Wiesbaden, Germany.
Allergol Select ; 8: 18-25, 2024.
Article en En | MEDLINE | ID: mdl-38549809
ABSTRACT

INTRODUCTION:

Eosinophilic granulomatosis with polyangiitis (EGPA) was formerly known as Churg-Strauss syndrome. The condition is characterized by disseminated necrotizing vasculitis with extravascular granulomas associated with hypereosinophilia. The vasculitides affect small vessels and are associated with antineutrophil cytoplasmic antibodies (ANCAs) detectable in the blood. Distinguishing between type 2-mediated chronic airway inflammation such as chronic rhinosinusitis with nasal polyps (CRSwNP) without vasculitis can be clinically challenging and should be considered. MATERIALS AND

METHODS:

Immunological background, diagnosis, and therapy of EGPA were identified through literature searches in Medline, PubMed, as well as national and international studies (ClinicalTrials.gov) and the Cochrane Library. Human studies published up to and including 10/2023 on the topic were considered.

RESULTS:

In cases of deteriorating general health with previously known eosinophilic inflammation of the upper and lower airways, EGPA and its interdisciplinary investigation should be considered. Various types of eosinophilic inflammation and syndromes must be considered differentially.

CONCLUSION:

Characterization of mucosal airway inflammation through biomarker determination is meaningful and occasionally makes the difference for targeted therapy.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Allergol Select Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Allergol Select Año: 2024 Tipo del documento: Article